Genmab

	13/5 15:41 af Solsen	Dont think Management exercised warrants. Normally the announcement comes shortly after the announcement of capital increase due to warrants.
	13/5 15:17 af GeorgeBest	It will come after closing. But only if management sell the shares.
	13/5 14:43 af GMAB	Still no press release regarding Management`s exercise of warrants?
	13/5 14:41 af Darvin	Ah mon ikke der skal smides lidt flere
	13/5 14:00 af Helge Larsen/PI-redaktør	Kan vi formode at udsalget af warrants er slut?
	13/5 13:37 af Solsen	BMY are fools
	13/5 13:24 af Darvin	:-)
	13/5 13:20 af E L	@Darvin if Helge would get 1dkk for every double link here, he could stop working lol, wouldn't worry about it ;-)
	13/5 13:17 af Darvin	Sorry El did not notice your link
	13/5 13:15 af Darvin	Yes - but here: On May 13, 2020, bluebird bio, Inc. (“bluebird”) and Bristol Myers Squibb Company announced that the companies received a Refusal to File letter from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for idecabtagene vicleucel (ide-cel; bb2121) for patients with heavily pre-treated relapsed and refractory multiple myeloma, which was submitted in March 2020.
	13/5 13:14 af E L	Blue just sold part of their rights to BMY 2 days ago for $200mio lol
	13/5 13:11 af GeorgeBest	Bluebird down 8% in premarked!
	13/5 13:08 af E L	Bristol Myers Squibb and bluebird bioannounced that the companies received a Refusal to File letter from the FDA on bb2121 (link)
	13/5 12:48 af Solsen	Jeg købte også lidt tilbage af det jeg solgte i går. Nu håber vi ikke abstracts ødelægger noget :-)
	13/5 12:36 af Parasitism	Jeg har købt i 1887,5 :-)
	13/5 12:03 af Bisseministeren	Hmm, tænker i at i dag er en god købsmulighed? :)
	13/5 11:32 af kkjoel	Sådan. Keep up the good work :-) Jeg har en liste, men opdaterer den noget uregelmæssigt...
	13/5 11:24 af GeorgeBest	Jeg har ikke lavet en liste, jeg poster bare når der offenliggøres nye kursmål på Bloomberg
	13/5 11:22 af kkjoel	Fino GB. Jeg har gennemsnitskursmål på 1724 fra 30 huse. 17 køb, 7 hold, 3 sælg og 3 n/a. Er det helt i skoven? Post evt. din liste i debatten...
	13/5 11:14 af GeorgeBest	Morningstar lower rating on Genmab from hold to sell, target unchanged at 1650
	13/5 11:13 af Legolas23	Vi taber 80 point. Nye aktier og den forudsete gevinsthjemtagelse.
	13/5 10:45 af concillado	Der må snar nogle nye partner/overtagelses-rygter til igen ;-)
	13/5 10:44 af concillado	Tak for påmindelsen om de nyudstedte aktier.. det havde jeg lige svedt ud, og rigtignok kombineret med lidt kort gevinsthjemtagning, så er det utroligt at vi ikke falder hurtigere!
	13/5 10:32 af AaBforever	Suverænt mest omsatte.

	13/5 10:21 af AaBforever	Bestemt. Det ville komme.
	13/5 10:01 af AaBforever	Der bliver handlet igennem i dag. 186 mill. på1 time. Mest omsatte C25.
	13/5 09:46 af E L	full pdf (link)
	13/5 09:45 af E L	Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors (link)
	13/5 09:25 af nohope	Noooo -Dara was done without time pressure - straight
	13/5 09:25 af nohope	A graphite moderated reactor a-la Tjernobyl - fired in the middle of a large town....
	13/5 09:24 af E L	that was Daratumumab :-D
	13/5 09:23 af nohope	The Manhattan project of our time ?
	13/5 09:21 af E L	the main focus for now for GEN1046 will be solid tumors anyway .
	13/5 09:20 af E L	i am not so sure about that lol, many other trials going on. But , as they say, under pressure everything becomes fluid, let's 'hope' they are successful ;-)
	13/5 09:17 af nohope	Yes, really comforting right ? The destiny of the world depends on a technique that has never had a positive outcome.
	13/5 09:16 af E L	sure. on the other hand, there has never been as much focus and as much research into mRNA as now, due to Covid, surely could lead to something
	13/5 09:14 af nohope	Well, I guess this what they call a really long shot in english.
	13/5 09:13 af E L	no, not yet
	13/5 09:12 af nohope	Has anybody ever gotten an approval for a mRNA vaccine ?
	13/5 09:09 af Sukkeralf	And both Genmab and BioNTech seems quite thrilled so far - actualy it could be even a bigger product than Darzalex but thats years ahead from now and lots of hills or even mountains to climb
	13/5 09:04 af Sukkeralf	I Guess so E L based on your comments from the transcript - lots of opportunities going forward with this program if the initial phase I/II data are good
	13/5 08:50 af E L	BioNTech is trying PD1-/PD-L1 Inhibitors with their mRNA Cancer vaccines in Melanoma; i wonder if this could be an area where the PD-L1x4-1BB duobody could be used instead?
	13/5 08:16 af E L	vaccines...?
	13/5 08:16 af E L	We believe it has broad potential in a range of solid tumors, including those where checkpoint therapy is currently established but also more difficult tumors where first-generation checkpoint inhibitors have not been as successful. This bispecific antibody has outperformed conventional checkpoint inhibitors in preclinical animal models. We have seen strong evidence in the preclinical setting of its ability to amplify the effect of our vaccines as well."
	13/5 08:16 af E L	"For our next-generation checkpoint-immune modulatory program partnered with Genmab, the ongoing trial with BNT311, the PD-L1x4-1BB dual body, continues to advance rapidly, as the expansion cohort has been initiated. Data from this Phase 1/2 trial in multiple solid tumors is expected in the second half of this year. We expect the updates to include dose escalation and safety data from the trial. We are excited about this program.
	13/5 08:16 af E L	From BioNTech SE (BNTX) Q1 2020 Earnings Call Transcript (link)
	13/5 08:10 af bibob	Nyt studie med Ofatumumab. ( ARTIOS ) . Ved ikke om det har været postet. (link)
	13/5 07:06 af Helge Larsen/PI-redaktør	dara vs Sarclisa (GEN): (link)
	13/5 06:54 af bibob	God morgen. :-)
	13/5 06:51 af Helge Larsen/PI-redaktør	God morgen. :-)